APAC Immunohistochemistry Market

APAC Immunohistochemistry Market Size (2024 to 2029)

As per our research report, the size of the Asia Pacific IHC Market was valued at USD 563.10 million in 2024. It is estimated to be growing at a CAGR of 7.2% and worth USD 797.19 million by 2029.

The market is predicted to grow substantially in the mentioned forecast period as well as years to follow. Immunohistochemistry is a medical procedure used for the diagnosis of cancer. It involves the staining of a fresh or preserved cancer tissue that is removed from the patient’s body during the biopsy. This diagnostic process helps in the detection of hormone receptors on the surfaces of cancer cells. Immunohistochemistry is used for the diagnosis of cancers as well as tumour antibodies. It is an essential procedure for doctors as it helps them to know the tissue distribution of an antibody.

The Asia-Pacific Immunohistochemistry market is driven by factors like the ever-increasing population of the continent, an increasing number of cancer patients, and an emerging economy and increased the ability to spend on healthcare.

The primary constraints for this market are lack of awareness among the people about new technologies in the medical sector, unstable reimbursement scenario, and massive capital requirement.

This research report on Asia-Pacific Immunohistochemistry Market has been segmented and sub-segmented into the following categories:

APAC Immunohistochemistry Market By Product

• Antibodies
• Reagents
• Equipment
• Kits

APAC Immunohistochemistry Market By Application

• Diagnostics
• Drug Testing

APAC Immunohistochemistry Market By End User

• Hospitals
• Diagnostic Laboratories
• Research Institutes

APAC Immunohistochemistry Market By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regional Analysis

Regionally, the Asia-Pacific immunohistochemistry market is showcasing the fastest growth rate in the world. Economic development in the short period across this region is one of a primary factors leading growth. Also, the growing number of cancer patients and increasing expenditure on healthcare are further majorly enhancing market growth.

Chinese immunohistochemistry market is currently leading the Asia Pacific market, and the future is estimated to be more lucrative as per our research analysis. The government of China is coming up with well-organized and necessary precision medicine steps taken for increasing the demand towards the immunohistochemistry market growth of the APAC region.

On the other hand, Indian immunohistochemistry market is estimated to grow at a healthy rate during the forecast period due to increasing elder people population, the average increase of chronic and infectious diseases, and growing aging population are the factors boosting the immunohistochemistry growth.

Key Companies Operating the Asia Pacific Immunohistochemistry Market Profiled in the Report are F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc.